Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
174
-
Total 13F shares, excl. options
-
79.8M
-
Shares change
-
+17.4M
-
Total reported value, excl. options
-
$860M
-
Value change
-
+$188M
-
Put/Call ratio
-
0.66
-
Number of buys
-
105
-
Number of sells
-
-65
-
Price
-
$10.77
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2019
231 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2019.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 174 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.8M shares
of 295M outstanding shares and own 27.09% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (11M shares), BlackRock Inc. (9.43M shares), VANGUARD GROUP INC (8.31M shares), WASATCH ADVISORS INC (6.6M shares), STATE STREET CORP (5.35M shares), Bellevue Group AG (3.65M shares), FMR LLC (2.68M shares), CREDIT SUISSE AG/ (2.36M shares), DIMENSIONAL FUND ADVISORS LP (1.96M shares), and CITADEL ADVISORS LLC (1.91M shares).
This table shows the top 174 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.